Latest News

Dr. Reddy's Laboratories Announces the Launch of Imatinib Mesylate Tablets, USP in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Imatinib Mesylate Tablets, USP, a therapeutic equivalent generic version of Gleevec (imatinib mesylate) Tablets in the United States market approved by the U.S. Food and Drug Administration (USFDA). The Gleevec brand and generic had U.S. sales of approximately $868 million MAT fo

Source link

Related posts

Fisherman Finds SpaceX Dragon Capsule Piece On Water And Fishes It Out


STAT Plus: Up and down the ladder: The latest comings and goings


2020 rings in new decade at Penn Medicine, closes chapter of big change


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World